NET PROFIT (x1000 SEK)
EMPLOYEES
Hamlet BioPharma AB
Closing information (x1000 SEK)
| Closing information | 2024/06 (consolidated) | 2023/06 (consolidated) | 2022/06 |
| Turnover |
0
|
0
|
0 |
| Financial expenses |
0
|
0
|
76 |
| Earnings before taxes |
-41,817
|
-20,441
|
-17,197 |
| EBITDA |
-32,930
|
-20,040
|
-17,112 |
| Total assets |
68,566
|
28,490
|
41,732 |
| Current assets |
27,300
|
19,014
|
41,732 |
| Current liabilities |
4,108
|
2,549
|
3,718 |
| Equity capital |
64,458
|
20,941
|
38,014 |
| - share capital |
1,678
|
1,120
|
1,105 |
| Employees (average) |
7
|
4
|
4 |
Financial ratios
| Fiscal year | 2024/06 (consolidated) | 2023/06 (consolidated) | 2022/06 |
| Solvency |
94.0%
|
73.5%
|
91.1% |
| Turnover per employee |
0
|
0
|
0 |
| Profit as a percentage of turnover | |||
| Return on assets (ROA) |
-61.0%
|
-71.7%
|
-41.0% |
| Current ratio |
664.6%
|
745.9%
|
1122.4% |
| Return on equity (ROE) |
-64.9%
|
-97.6%
|
-45.2% |
| Change turnover |
0
|
0
|
0 |
| Change turnover % | |||
| Chg. No. of employees |
3
|
0
|
0 |
| Chg. No. of employees % | 75% | 0% |
Total value of public sale
| Fiscal year | 2024/06 (consolidated) | 2023/06 (consolidated) | 2022/06 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.